Keytruda is expected to drive another strong quarter for MRK, with investors watching Q2 sales and management's outlook ahead ...
7hon MSNOpinion
The patent cliff could cost billions: How Bayer and Merck & Co. respond—and how Vidac Pharma is gaining momentum
Bayer Fights on Several Fronts Under the leadership of Bill Anderson, the Leverkusen-based Bayer Group is facing a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results